Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Despite Paclitaxel Warnings, Physicians Endorse Boston Sci’s Eluvia Stent For NTAP In CMS Pay Proposal Comments

Executive Summary

Cardiologists and radiologists spoke in support of new technology add-on payments for Boston Scientific’s Eluvia drug-eluting stent, used to treat patients with peripheral artery disease, in comments on the US Medicare agency's Inpatient Prospective Payment System (IPPS) rule for 2020, despite concerns about paclitaxel-coated stents discussed at a late June US FDA Advisory Committee meeting.

Advertisement

Related Content

Panelists Grapple With Unclear Data At Paclitaxel Meeting
FDA Tells Providers To Limit Use Of Paclitaxel-Coated Stents
SCAI, Manufacturers Defend Peripheral Paclitaxel Devices Against Doubts

Topics

Advertisement
UsernamePublicRestriction

Register

MT125352

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel